The thesis seemed to be that an ED drug for women would have atruely huge market. So this was a low probability but very highpayoff bet that the drug would be approved. The company still hassome cash, so it has some time to work things out.I personally won't touch companies with no earnings,but some people like to spread a lot of small bets on earlystage drug companies and hope that the winners more than make upfor the losers.As for the number of stars, that is done on the number of outperforms versus under performs, modulated by the standing of theraters. In a thinly followed stock, some adventurous raters canhave a lot of say. You still need to do your own due dilligence.Chris - personally avoids small pharma like the plague
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ra